Emma-Anne Karlsen is researching ways to enhance the effectiveness of monoclonal antibodies (mAb) in cancer treatment, addressing the issue of low response rates (below 35%) in certain cancers, costing Australia an estimated $355 million annually for non-responders. Her solution involves repurposing prochlorperazine (PCZ), a low-cost hospital medication, to transform non-responders into responders.

Further Activities to have a look at